AstraZeneca stock edges higher as investors eye oncology milestones and valuation gap
Published on 09/04/2026 at 18:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock (ISIN GB0009895292) is trading around 121.64 GBP on the London Stock Exchange as of September 4, 2026, after gaining about 0.1 percent intraday according to data reported by Finanzen.
Stock performance and DACH angle
According to an intraday overview published on September 4, 2026, by Finanzen, AstraZeneca shares rose to 121.64 GBP in London, up 0.1 percent from the session open at 121.46 GBP and after touching an intraday high of 121.74 GBP.
Market data compiled by Ad Hoc News show that AstraZeneca stock closed at 164.02 USD on the New York Stock Exchange as of September 3, 2026, which represented a daily gain of 1.48 percent but left the shares down about 10.7 percent year to date compared with a gain of 10.6 percent for a biomedical and genetics industry index.
Analyst view and valuation gap
A same day analysis on September 4, 2026 from Gurufocus highlighted that AstraZeneca stock traded at 164.77 USD while the platform's GF Value metric stood at 181.78 USD, implying the shares were approximately 9.4 percent below this intrinsic value estimate.
The same Gurufocus piece on September 4, 2026 underscored AstraZeneca's dividend profile, noting that the valuation gap between the 164.77 USD market price and the 181.78 USD GF Value supported an argument that AstraZeneca stock might be modestly undervalued relative to its long term fundamentals.
More AstraZeneca stock coverage
Further news, filings and analysis on AstraZeneca stock can be found in the dedicated topics section.
Oncology pipeline milestones
On September 4, 2026 a report by Gurufocus noted that AstraZeneca had received orphan drug designation from the United States Food and Drug Administration for a novel therapy targeting hepatocellular carcinoma, reinforcing the company's strategic emphasis on oncology.
Separately, a newswire carried by the Manila Times on September 4, 2026 reported that C4X Discovery Holdings would receive a milestone payment of 13 million USD from AstraZeneca after an oral NRF2 activator program entered clinical development, illustrating how AstraZeneca's collaboration pipeline can translate into concrete financial commitments.
Representative product spotlight
AstraZeneca generates a significant portion of its revenue from oncology and cardiovascular medicines, with flagship therapies in lung cancer, breast cancer and cardiovascular disease underpinning its growth strategy in recent reporting periods.
Stock level and investor takeaway
Based on data from Finanzen as of September 4, 2026, AstraZeneca stock last traded at 121.64 GBP in London, with the intraday move of 0.1 percent leaving the shares below their year to date starting level even as some valuation metrics such as the 181.78 USD GF Value cited by Gurufocus stand above the recent New York price of 164.77 USD.
AstraZeneca stock key data
- Company: AstraZeneca PLC
- ISIN: GB0009895292
- Ticker: AZN
- Trading venue: London Stock Exchange and New York Stock Exchange
- Price (as of September 4, 2026, 12:28): 121.64 GBP
- Sector / Industry: Pharmaceuticals and biotech
- Index membership: FTSE 100
